Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opinion & Analysis Pieris Pharmaceuticals Inc PIRS

Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4... see more

Opinion & Analysis (NDAQ:PIRS)

    2017 Small-Cap Biotech Watchlist update: up 21% at the end of Q2/17

    The Life Sciences Report July 14, 2017

    2017 Small-Cap biotech watchlist update: holding steady in a volatile market

    The Life Sciences Report April 21, 2017

    19 companies selected for the 2017 Small-Cap Biotech Watchlist

    The Life Sciences Report January 5, 2017

    Seven biotech names on the upswing: 2016 small-cap biotech watchlist update

    The Life Sciences Report March 11, 2016